VJOncology is committed to improving our service to you

ASCO 2018 | Pazopanib for progressive desmoid tumors

VJOncology is committed to improving our service to you

Maud Toulmonde

There have previously been no randomized trials assessing systemic therapy activity for progressive desmoid tumors. Here, Maud Toulmonde, MD, of the Institut BergoniƩ, Bordeaux, France, discusses the aims, methods and results of the DESMOPAZ trial (NCT01876082). This French Sarcoma Group trial investigated the use of pazopanib vs. IV methotrexate/vinblastine in desmoid tumors. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter